Faculty

Needs Statement

Higher opioid prescribing puts patients at risk for addiction and overdose. According to the CDC (2016) since 1999 more than 165,000 people have died of an overdose related to prescription opioids and as many as 1 in 4 persons with chronic pain treated in primary care are prescribed opioids (approximately 50% of all prescribed opiates) and struggle with addiction. But chronic pain is also a significant issue. About 11% of Americans struggle with daily (chronic) pain. There is insufficient evidence that prescription opioids control chronic pain effectively over the long term, and there is evidence that other treatments can be effective with less harm. The need for alternative strategies from opiates for pain management and clear guidelines for use of opiates for chronic pain when no alternatives exist have led the CDC to develop Guidelines for Prescribing Opiates for Chronic Pain (2016). 

Target Audience

Healthcare professionals in a primary care setting.

Objectives

At the end of this presentation participants should be able to:
1. Identify Non-opioid treatment modalities for pain
2. Discuss non-opiate medications and potential risks associated with their use for chronic pain
3. Apply guiding principles for treating chronic pain with and without opiates
4. Compare qualitative versus quantitative urine drug screens
5. Develop a controlled substance agreement using typical components

Accreditation

In support of improving patient care, University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME
This enduring material is designated for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

This training has been approved by the KBML as meeting the statutory requirements of HB1. 0521-H1.0-UK14C

IPE Competencies

• Roles/ Responsibilities
• Interprofessional Communication

CPE
This knowledge-based activity will award 1.00 contact hour (0.100 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

Other
UK Healthcare CECentral certifies this activity for 1.00 hour of participation.

ASWB ACE
As a Jointly Accredited Organization, UK HealthCare CECentral is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. UK HealthCare CECentral maintains responsibility for this course. Social workers completing this course receive 1.00 clinical continuing education credit.

CNE
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.00 nursing contact hour.

Faculty Disclosure

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months.  An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

None of the planners, faculty, and others in control of educational content for this educational activity have relevant financial relationship(s) to disclose with ineligible companies.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Acknowledgement

The activity was supported by Anthem.